Skip to main content

Table 3 Coefficients of the brain, liver, spleen, heart and kidney

From: Toxicity evaluation of zinc aluminium levodopa nanocomposite via oral route in repeated dose study

Groups Body weight (g) Brain (mg/g) Liver (mg/g) Heart (mg/g) Spleen (mg/g) Kidney (mg/g)
ZALH (n = 8) 300 ± 25 5.61 ± 0.93 35.67 ± 1.53 4.00 ± 0.53 1.99 ± 0.37 4.19 ± 0.20
ZALL (n = 8) 342 ± 30 5.76 ± 0.55 36.27 ± 3.35 3.90 ± 0.53 2.08 ± 0.20 4.16 ± 0.22
ZAH (n = 8) 337 ± 25 5.62 ± 0.31 30.14 ± 3.54 3.91 ± 0 .43 2.32 ± 0.26 3.98 ± 0. 23
ZAL (n = 8) 335 ± 47 5.22 ± 0.68 31.83 ± 4.12 4.50 ± 0.44 2.29 ± 0.19 3.93 ± 0.45
VC (n = 8) 332 ± 14 5.31 ± 0.70 28.25 ± 2.71 3.86 ± 0 .35 1.88 ± 0.19 3.59 ± 0.39
  1. Mean coefficient of brain, liver, spleen, heart and kidney of all the groups. The coefficients of organs from the four treated groups were almost similar to those of the control. Statistical test used to compare the means of each group against the control group was done using one-way ANOVA; it shows no significant difference with p > 0.05. Zinc-aluminium levodopa nanocomposite high dose (ZALH 500 mg/kg), zinc-aluminium levodopa nanocomposite low dose (ZALL 5 mg/kg), zinc-aluminium nanocomposite high dose (ZAH 500 mg/kg), zinc-aluminium nanocomposite low dose (ZAL 5 mg/kg), vehicle control (VC normal saline 100 ml/kg body weight).